Cardiac amyloidosis is becoming increasingly important among cardiologist and an early diagnosis is very important. Amyloidosis is a systemic disease and many cardiac and extracardiac elements (red flags) should raise the suspicion of the disease. Electrocardiographic and imaging techniques (such as echocardiography, cardiac magnetic resonance and scintigraphy) are useful tools to make a diagnosis together with the presence of orthopedic issues, peripheral neuropathy or plasma cell dyscrasia. Cardiac amyloidosis is also often associated with valvular disorder, heart failure or cardiomyopathy. Red flags are crucial to raise suspicion and reach an early diagnosis, in order to start a targeted treatment strategy that could change the patient's outcome. Indeed, in the last years four new drugs were approved to treat transthyretin amyloidosis.

Maloberti, A., Ciampi, C., Politi, F., Fabbri, S., Musca, F., Giannattasio, C. (2024). Cardiac amyloidosis red flags: What all the cardiologist have to know. INTERNATIONAL JOURNAL OF CARDIOLOGY. CARDIOVASCULAR RISK AND PREVENTION, 21(June 2024) [10.1016/j.ijcrp.2024.200271].

Cardiac amyloidosis red flags: What all the cardiologist have to know

Maloberti A.
;
Ciampi C.;Politi F.;Fabbri S.;Giannattasio C.
2024

Abstract

Cardiac amyloidosis is becoming increasingly important among cardiologist and an early diagnosis is very important. Amyloidosis is a systemic disease and many cardiac and extracardiac elements (red flags) should raise the suspicion of the disease. Electrocardiographic and imaging techniques (such as echocardiography, cardiac magnetic resonance and scintigraphy) are useful tools to make a diagnosis together with the presence of orthopedic issues, peripheral neuropathy or plasma cell dyscrasia. Cardiac amyloidosis is also often associated with valvular disorder, heart failure or cardiomyopathy. Red flags are crucial to raise suspicion and reach an early diagnosis, in order to start a targeted treatment strategy that could change the patient's outcome. Indeed, in the last years four new drugs were approved to treat transthyretin amyloidosis.
Articolo in rivista - Review Essay
Cardiac amyloidosis; Red flag; Transthyretin;
English
27-apr-2024
2024
21
June 2024
200271
none
Maloberti, A., Ciampi, C., Politi, F., Fabbri, S., Musca, F., Giannattasio, C. (2024). Cardiac amyloidosis red flags: What all the cardiologist have to know. INTERNATIONAL JOURNAL OF CARDIOLOGY. CARDIOVASCULAR RISK AND PREVENTION, 21(June 2024) [10.1016/j.ijcrp.2024.200271].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/476019
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
Social impact